Psoriasis y enfermedad cardiovascular 1º Edición

Edición: 1ª
Autores: Álvaro González Cantero, Luis Rodríguez Padial, Joel Gelfand
Editorial: Aula Médica
ISBN: 9788478856657
Formato: Rústica/Paperback 14×24
Nº volumenes: 1
Páginas: 100
Año publicación: Enero 2020

Descripción:

Prólogo

Psoriasis and Cardiovascular Disease edited by Drs González-Cantero and Padial is a welcome and necessary addition to the literature that will advance the science and clinical practice of this important topic. The concept that psoriasis may promote cardiovascular disease is at least over a century old, with literature dating to the 1800’s describing diabetes in patients with psoriasis. Fast forward to the modern era in which advances in immunology, genetics, and medical informatics have resulted in an explosion of knowledge with important scientific and clinical implications. In the last several years alone, there are about 250 publications per year about the topic of psoriasis and cardiovascular disease and major medical organizations across the world have addressed this topic in clinical practice guidelines. This book, therefore, is timely and necessary and distills an enormous amount of knowledge relevant to researchers and clinicians alike.

Our current knowledge is that patients with psoriasis have an increased risk of major cardiovascular events and mortality. This risk increases with increasing severity of skin disease measured indirectly (based on treatment patterns) or directly, based on body surface area affected by psoriasis. This relationship appears to be independent of traditional cardiovascular risk factors, however, the causal nature of this relationship has not been proven. While many will debate the causal nature of the relationship of psoriasis and cardiovascular disease, there is ample evidence of a biological basis for this association, which is carefully detailed in this book. Furthermore, definitive evidence that treatment of psoriasis will bend the comorbidity curve and lead to a lower risk of cardiovascular disease and mortality is lacking and remains a key knowledge gap. That said, emerging data is more carefully detailing the cardiometabolic effects of psoriasis treatment often with surprising findings. While we do not know for certain that treatment of psoriasis will have cardiovascular benefits, we do know for certain that patients with psoriasis have a higher frequency of traditional cardiovascular risk factors and that these risk factors are often not identified or not treated adequately, and therefore, the is great opportunity to improve our patients lives, both in quality and quantity of years, through the evidence based application of screening and treatment of traditional CV risk factors such as hypertension, diabetes, and dyslipidemia. This book will help the clinician implement these prevention strategies and will inform researchers of the need to better understand how to best prevent cardiovascular disease in this vulnerable population.

JOEL M. GELFAND
September 17, 2019

Joel M. Gelfand MD MSCE is Professor of Dermatology and Epidemiology (with tenure) at the University of Pennsylvania’s Perelman School of Medicine. He is also Vice Chair of Clinical Research, Medical Director of the Dermatology Clinical Studies Unit, and Director of the Psoriasis and Phototherapy Treatment Center. He is a nationally and internationally recognized expert in psoriasis, clinical epidemiology, drug safety, and clinical trials. Dr. Gelfand is the author of over 260 scientific publications, editorials, reviews, and text book chapters (cited over 18,000 times, H index 60) which appear in journals such as JAMA, BMJ, European Heart Journal, Annals of Rheumatic Disease, JAMA Dermatology, JAAD, and the JID. He is the recipient of the American Skin Association’s Psoriasis Achievement Award, PENN’s New Investigator Marjorie Bowman Award and the Lady Barbara Colyton’s Award for Autoimmune research, Penn’s Department of Biostatistics and Epidemiology’s epidemiology teaching award, NPF’s inaugural award for scientific achievement, and is an elected member of the American Society for Clinical Investigation. He has given over 10 named lectureships and keynote addresses including the Society for Investigative Dermatology’s Eugene M. Farber lecture and the American Academy of Dermatology’s Marion B. Sulzberger lecture. He has received grant support from NIH, FDA, PCORI, the Dermatology Foundation, the American Skin Association, the National Psoriasis Foundation, and numerous pharmaceutical companies to support his independent research program. The overarching goal of his research and clinical practice is to improve psoriasis patient outcomes in the skin and joints, while lowering the risk of diabetes, CV disease and mortality.

Índice

Prólogo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . VII
Dr. Joel Gelfand

Psoriasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Dra. Elena Martínez Lorenzo y Dra. Cristina Pérez Hortet

Prevención cardiovascular . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Dr. Luis Rodríguez Padial

Aspectos epidemiológicos de la psoriasis y la enfermedad cardiovascular . . . . . . . . . . . . . . . 29
Luca Schneller-Pavelescu Apetrei y Dra. Isabel Belinchón

Psoriasis y factores de riesgo cardiovascular. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
Antonio Martínez López y Salvador Arias Santiago

Psoriasis y enfermedad cardiovascular: patogenia y vías inflamatorias comunes . . . . . . . . . 47
Dra. Natalia Jiménez Gómez y Dr. Álvaro González Cantero

Efecto de las terapias biológicas en el riesgo cardiovascular de los pacientes con psoriasis . . . . . . . . . . . . . . . . . . . . . . 57
Dra. Ana Isabel Sánchez Moya y Dr. Álvaro González Cantero

Prevención y tratamiento de la enfermedad cardiovascular en pacientes con psoriasis: aspectos prácticos . . . . . . . . . . . . 67
Dr. Álvaro González Cantero y Dr. Luis Rodríguez Padial

Detección de riesgo cardiovascular en psoriasis mediante técnicas de imagen no invasivas: algoritmo de actuación . . . . . . . . . . 75
Dr. Álvaro González Cantero y Dr. Luis Rodríguez Padial

Perspectivas de futuro: biomarcadores de estratificación de riesgo cardiovascular en pacientes con psoriasis. . . . . . . . . . . . . . . 83
Dr. María Eugenia González-Barderas y Dr. Álvaro González Cantero

Propuesta de organización de una unidad de atención integral de la psoriasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
Dr. Álvaro González Cantero y Dr. Luis Rodríguez Padial